Short-Course Ruxolitinib Initiated at Neutrophil Engraftment for Prevention of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter, Randomized, Open-Label, Controlled Phase II Trial.
Huan Hua, Xuan Liu, Shupeng Wen, Ying Wang, Zhiyun Niu, Zhengrong Song, Ziwei Zhou, Li Sun, Zheng Xu, Jing Yuan, Xinzhi Han, Zhenzhen Wang, Feng Gao, Shuqing Feng, Guohong Su, Tao Wang, Liangming Ma, Jianping Zhang, Nannan Li, Hang Li, Xuejun Zhang, Fuxu Wang
Transplant Cell Ther S2666-6367(26)00846-8
摘要
摘要
Acute graft-versus-host disease (aGVHD) remains a leading cause of non-relapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). On the cyclosporine A (CsA)/methotrexate (MTX)/mycophenolate mofetil (MMF) backbone, MMF withdrawal around engraftment creates an immunosuppression gap coinciding with peak peri-engraftment alloreactivity. To test whether a 14-day ruxolitinib course initiated at confirmed neutrophil engraftment, within a donor-stratified MMF discontinuation schedule, reduces the 100-day cumulative incidence of grade II to IV aGVHD versus standard prophylaxis alone. Multicenter, randomized, open-label, phase II superiority trial (ChiCTR1900027971) at 5 transplant centers in North China (December 2019 to August 2022). A total of 171 patients (aged 12 to 66 years) with hematologic malignancies or severe aplastic anemia (SAA) were randomly assigned 1:1 to ruxolitinib plus standard prophylaxis (n=86) or standard prophylaxis alone (n=85). MMF was discontinued per a donor-stratified schedule: full withdrawal at engraftment for matched sibling recipients; half-dose at engraftment, discontinuation by day +30 for matched unrelated and haploidentical recipients. Ruxolitinib (5 mg twice daily for 7 days, then 5 mg once daily for 7 days; total 105 mg) was started at confirmed neutrophil engraftment. The primary endpoint was the 100-day cumulative incidence of grade II to IV aGVHD, with death without prior aGVHD as a competing event (Fine-Gray model). Data cutoff: December 31, 2023. The 100-day cumulative incidence of grade II to IV aGVHD was 14.0% (12/86) versus 34.1% (29/85) (subdistribution hazard ratio [sHR] 0.35, 95% confidence interval [CI] 0.18 to 0.68; P = .002), an absolute reduction of 20.1% (number needed to treat [NNT] 5.0, 95% CI: 3.1 to 13.0). Grade III to IV aGVHD was 7.0% versus 16.5% (sHR 0.37, 95% CI: 0.14 to 0.98; P = .047). All 85 treated patients completed the 14-day course without dose modification; grade ≥3 adverse events within 100 days were similar between arms. Pre-transplant measurable residual disease (MRD) positivity was unbalanced between arms (63.5% versus 45.9%; P = .032), potentially confounding survival comparisons. Two-year overall survival (OS) was 81.4% versus 82.4% (HR 0.89, 95% CI: 0.45 to 1.75; P = .674). Among 150 patients with hematologic malignancies, 2-year NRM was 8.1% versus 11.8% (sHR 0.63, 95% CI: 0.26 to 1.53; P = .308), relapse 16.2% versus 11.8% (sHR 1.11, 95% CI: 0.53 to 2.32; P = .782; MRD-adjusted sHR 0.95, 95% CI: 0.44 to 2.06), disease-free survival 75.7% versus 76.3% (HR 0.92, 95% CI: 0.48 to 1.76; P = .834), and GVHD-free, relapse-free survival 64.9% versus 56.6% (HR 0.76, 95% CI: 0.47 to 1.23; P = .247). The aGVHD benefit was consistent across all prespecified subgroups (all P for interaction >.10). Short-course ruxolitinib initiated at neutrophil engraftment reduced grade II to IV aGVHD by 20.1% (NNT 5.0), with an acceptable safety profile and no evidence of impaired graft-versus-leukemia effect after MRD balancing. Survival endpoints may be confounded by the MRD imbalance, steroid-refractory aGVHD crossover, and relapse predominance. MRD-stratified phase III trials are warranted.
KM 提取结果
0 个 Figure · 0 个 KM 面板